Plasma levels of soluble TNF receptors are associated with cardiac function in patients with Chagas heart disease

• Published in: International journal of cardiology Vol. 316; pp. 101 - 103
• Main Authors: Silva, Whesley Tanor, Costa, Henrique Silveira, Lima, Vanessa Pereira de, Xavier, Diêgo Mendes, Mendonça, Vanessa Amaral, Lacerda, Ana Cristina Rodrigues, Lage, Vanessa Kelly da Silva, Lima, Márcia Maria Oliveira, Rocha, Manoel Otávio Costa, Figueiredo, Pedro Henrique Scheidt
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2020
• Subjects: Cardiovascular Physiological Phenomena; Chagas cardiomyopathy; Echocardiogram; Female; Heart Diseases; Humans; Inflammation; Male; Middle Aged; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Tumor necrosis factor; Tumor Necrosis Factor-alpha; Echocardiogram; Inflammation; Tumor necrosis factor; Chagas cardiomyopathy
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2020.04.053

The soluble receptors tumor necrosis factor-alpha (sTNFRs) can lead to an increase in the expression of tumor necrosis factor, increasing its detrimental to systemic inflammatory activation in Chagas cardiomyopathy (ChC). However, the correlation between sTNFRs levels, echocardiographic, and functional levels in patients with ChC remains unknown. This study aimed to verify the correlation between the plasma sTNFRs levels, echocardiographic, and NYHA functional levels in patients with ChC. Sixty-four patients with ChD (54 ± 2 years, 44% males, NYHA I-II) were evaluated by anamnesis protocol, echocardiography, and plasma sTNFR1 and sTNFR2 measurement. Linear regression analysis and Student's t-test were used as appropriate. Higher plasma sTNFR1 and sTNFR2 levels were associate with worse systolic function (R2 = 0.10; p = 0.008 and R2 = 0.44; p < 0.001) and cardiac dilation (R2 = 0.13; p = 0.002 and R2 = 0.43; p < 0.001). Patients with systolic dysfunction and cardiac dilatation had higher sTNFRs levels (p < 0.001). There were no significant differences among NYHA functional classes for both sTNFRs. Plasma sTNFR1 and sTNFR2 levels are associated with greater cardiac dilation and poor systolic function in ChC patients. •Plasma sTNFRs levels are related to poor prognosis in patients with heart disease.•Cardiac dysfunction was associated with higher plasma sTNFRs levels in ChC patients.•Plasma sTNFRs levels were similar among the ChC patients with NYHA classes I and II.